The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Perides, George ^a,b   Zhuge, Yuzheng ^a   Lin, Tina ^a   Stins, Monique F ^c   Bronson, Roderick T ^d   Wu, Julian K ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; PLASMIN; PLASMINOGEN; ANTIFIBRINOLYTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPERIMENTAL NEOPLASM; FIBRINOLYSIS; MELANOMA; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROGNOSIS; SURVIVAL TIME; TUMOR VOLUME; WILD TYPE; ANIMAL; BRAIN; BRAIN TUMOR; C57BL MOUSE; CANCER INVASION; CAROTID ARTERY; CELL CULTURE; CELL MOTION; CYTOLOGY; EXPERIMENTAL MELANOMA; GENETICS; HUMAN; INJECTION; METASTASIS; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN TUMOR; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

6-AMINOCAPROIC ACID; ANIMALS; ANTIFIBRINOLYTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CAROTID ARTERIES; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; INJECTIONS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; PLASMINOGEN; SKIN NEOPLASMS;

EID: 33645463248     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-56     Document Type: Article

References (44)

1. Levin VA, Sheline GE, Cutin PH: Neoplasms of the central nervous system. In Cancer Principles and Practice of Oncology 4th edition. Edited by: De Vita VTJ, Hellman S and Rosenberg SA. Philadelphia, J.B. Lippincott Company; 1993:1679-1737.
2. Posner JB: Neurologic complications of cancer. Philadelphia, F.A. Davis Company; 1995.
3. Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol 1978, 19:579-591.
4. Sawaya R, Bindal RK: Metastatic brain tumors. In Brain tumors Edited by: Kaye AH and Laws JER. Edinburgh, Churchill Livingstone; 1995:923-946.
5. Arbit E, Wronski M: Clinical decision making in brain metastases. Neurosurg Clinics North Am 1996, 7:447-457.
6. Patchell RA: The treatment of brain metastases. Cancer Invest 1996, 14:169-177.
7. Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teichler BA, Reich E, Warren D, Lynch C, Richardson P, Snipper L, Frei E, Antman K: Double dose of intensive chemotherapy with autologous stem cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and caboplatin. J Clin Oncol 1996, 14:2984-2992.
8. Thorgeirsson UP, Lindsay CK, Cottam DW, Gomez DE: Tumor invasion, proteolysis, and angiogenesis. J Neuro-Oncol 1994, 18:89-103.
9. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasminogen system. FASEB J 1995, 9:939-945.
10. Vassalli JD, Sappino AP, Belin D: The plasminogen activator/plasmin system. J Clin Invest 1991, 88:1067-1072.
11. Sober AJ, Koh HK, Tran NLT, Washington CBJ: Melanoma and other skin cancers. In Harrison's Principles of Internal Medicine 14th edition. Edited by: Fauci AS, Braunwald E, Isselbacher JJ, D. WJ, Martin JB, Kasper DL, Hauser SL and Longo DL. New York, McGraw-Hill; 1998:543-549.
12. Stins MF, Gilles F, Kim KS: Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol 1997, 76:81-90.
13. Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M: A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol 1997, 158:3499-3510.
14. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D: Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995, 92:2585-2593.
15. Schackert G, Fidler IJ: Development of in vivo models for studies of brain metastasis. Int J Cancer 1988, 41:589-594.
16. Hughes WL, Commerford SL, Gitlin D, Krueger RC, Schultze B, Shah V, Reilly P: Deoxyribonucleic acid metabolism in vivo: cell proliferation and death as measured by incorporation and elimination of iododeoxyuridine. Fed Proc 1964, 23:640-648.
17. Schackert G, Price JE, Bucana CD, Fidler IJ: Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int J Cancer 1989, 44:892-897.
18. Sawaya R, Mandybur T, Ormsby I, Tew JMJ: Antifibrinolytic therapy of experimentally grown malignant brain tumors. J Neurosurg 1989, 64:263-268.
19. Brockway WJ, Castellino FJ: The mechanism of the inhibition of plasmin activity by e-aminocaproic acid. The Journal of Biological Chemistry 1971, 246:4641-4647.
20. Stins MF, Prasadarao NV, Zhou J, Arditi M, Kim KS: Bovine brain microvascular endothelial cells transfected with SV40-large T antigen: development of an immortalized cell line to study pathophysiology of CNS disease. In Vitro Cell Dev Biol Anim 1997, 33:243-247.
21. Butler WB, Kirkland WL, Jorgensen TL: Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). Biochemical & Biophysical Research Communications 1979, 90:1328-1334.
22. Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermontt E, Fennelly JJ, O'Higgins N: Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme & Protein 1996, 49:85-93.
23. Ronne E, Hoyer-Hansen G, Brunner N, Pedersen H, Rank F, Osborne CK, Clark GM, Dano K, Grondahl-Hansen J: Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treatm 1995, 33:199-207.
24. Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L, Graeff H: Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler 1992, 373:611-622.
25. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano K, Degen JL: Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998, 16:3097-3104.
26. Praus M, Wauterickx K, Collen D, Gerard RD: Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther 1999, 6:227-236.
27. Praus M, Collen D, Gerard RD: Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer 2002, 102:584-591.
28. Szende B, Okada Y, Tsuda Y, Horvath A, Bokonyi G, Okamoto S, Wanaka K, Keri G: A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. In Vivo 2002, 16:281-286.
29. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). International Journal of Cancer 1995, 63:840-845.
30. Xing RH, Rabbani SA: Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. International Journal of Cancer 1996, 67:423-429.
31. Stetler-Stevenson WG: Progelatinase A activation during tumor cell invasion. Invasion Metastasis 1994, 14:259-268.
32. Maguire T, Chin D, Souta D, Duffy MJ: Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. International Journal of Cancer 2000, 85:457-459.
33. Stahl A, Mueller BM: Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. International Journal of Cancer 1997, 71:116-122.
34. Ignar DM, Andrews JL, Witherspoon SM, Leray JD, Clay WC, Kilpatrick K, Onori J, Kost T, Emerson DL: Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis 1998, 16:9-20.
35. Ma D, Gerard RD, Li XY, Alizadeh H, Niederkorn JY: Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 1997, 90:2738-2746.
36. Gundersen D, Tran-Thang C, Sordat B, Mourali F, Ruegg C: Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J Immunol 1997, 158:1051-1060.
37. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997, 100:58-67.
38. Barilla ML, Carsons SE: Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum 2000, 29:252-265.
39. Chen ZL, Strickland S: Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997, 91:917-925.
40. Silletti S, Mei F, Sheppard D, Montgomery AM: Plasmin-sensitive dibasic sequences in the third fibronectin-like domain of L1-cell adhesion molecule (CAM) facilitate homomultimerization and concomitant integrin recruitment. J Cell Biol 2000, 149:1485-1502.
41. Cairns RA, Khokha R, Hill RP: Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med 2003, 3:659-671.
42. Arnold SM, Young AB, Munn RK, Patchell RA, Nanayakkara N, Markesbery WR: Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin Cancer Res 1999, 5:4028-4033.
43. Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H, Matsuura N: Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 2004, 64:4190-4196.
44. Gijbels K, Galardy RE, Steinman L: Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. Journal of Clinical Investigation 1994, 94:2177-2182.